Cargando…
Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression
INTRODUCTION: The co-regulatory molecule, HVEM, can stimulate or inhibit immune function, but when co-expressed with BTLA, forms an inert complex preventing signaling. Altered HVEM or BTLA expression, separately have been associated with increased nosocomial infections in critical illness. Given tha...
Autores principales: | Wakeley, Michelle E., Armstead, Brandon E., Gray, Chyna C., Tindal, Elizabeth W., Heffernan, Daithi S., Chung, Chun-Shiang, Ayala, Alfred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248445/ https://www.ncbi.nlm.nih.gov/pubmed/37305124 http://dx.doi.org/10.3389/fmed.2023.1176602 |
Ejemplares similares
-
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
por: Battin, Claire, et al.
Publicado: (2022) -
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding
por: Spodzieja, Marta, et al.
Publicado: (2020) -
BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021) -
A crucial role for HVEM and BTLA in preventing intestinal inflammation
por: Steinberg, Marcos W., et al.
Publicado: (2008) -
Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
por: Lan, Xiuwen, et al.
Publicado: (2017)